Artisan Partners Limited Partnership Raises Position in IQVIA Holdings Inc. $IQV

Artisan Partners Limited Partnership grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,433,957 shares of the medical research company’s stock after buying an additional 161,085 shares during the quarter. Artisan Partners Limited Partnership owned approximately 2.02% of IQVIA worth $652,246,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of IQV. Physician Wealth Advisors Inc. grew its position in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. Westside Investment Management Inc. raised its holdings in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the period. Atlantic Union Bankshares Corp purchased a new position in shares of IQVIA during the 3rd quarter worth about $36,000. Root Financial Partners LLC purchased a new stake in shares of IQVIA in the third quarter worth approximately $43,000. Finally, Hantz Financial Services Inc. boosted its stake in shares of IQVIA by 92.0% during the third quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 115 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 5.1%

IQV opened at $170.21 on Friday. The business’s 50 day moving average price is $213.03 and its 200 day moving average price is $207.86. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a market capitalization of $28.88 billion, a PE ratio of 21.66, a P/E/G ratio of 1.56 and a beta of 1.37. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IQV. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Evercore restated an “outperform” rating and issued a $225.00 target price on shares of IQVIA in a research note on Thursday, February 5th. TD Cowen increased their price objective on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group decreased their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $231.80.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.